Industry News

• Boston Scientific completes enrollment in PLATINUM trials  Boston Scientific announced completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program that are designed to compare the platinum chromium PROMUS® Element Everolimus-Eluting Stent System to matched historical control groups of patients.
  Boston Scientific Corporation March 16, 2010  
• New PLATO sub-analysis of CABG patients presented at ACC  AstraZeneca announced results of a new analysis of the PLATO study which showed there were fewer deaths in patients with acute coronary syndromes who took the investigational oral antiplatelet BRILINTA within seven days prior to having heart bypass surgery compared to those who took clopidogrel.
  AstraZeneca March 16, 2010  
• ARIAD reports development progress and fourth quarter and year-end 2009 financial results  ARIAD Pharmaceuticals reported a net loss of $80.0 million for the full year ended December 31, 2009 versus a net loss of $71.1 million for the same period in 2008, and cash used in operations was $51.9 million, compared to cash used in operations of $48.3 million for the same period in 2008.
  ARIAD Pharmaceuticals, Inc. March 16, 2010  
• Additional $162 million in Recovery Act investment to advance health IT  U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced awards to help states facilitate health information exchange and advance health information technology (health IT).
  Dept. of Health & Human Services March 15, 2010  
• Lilly to acquire global license to AXIRON testosterone solution from Acrux  Eli Lilly and Company and Acrux announced that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)).
  Eli Lilly and Company March 15, 2010  
• Molecular Insight Pharmaceuticals receives NASDAQ notification letter  Molecular Insight Pharmaceuticals announced the Company received a letter from The NASDAQ Stock Market notifying the Company that for the 30 consecutive business days the Company's listed securities did not meet the minimum $50 million Market Value of Listed Securities requirement.
  Molecular Insight Pharmaceuticals, Inc. March 15, 2010  
• Intensive Lipitor therapy was associated with reduced risk of cardiovascular events  Lipitor(R) (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome.
  Pfizer Inc. March 15, 2010  
• Cubist Pharmaceuticals President and CEO Michael Bonney honored  Cubist Pharmaceuticals announced that its President and CEO Michael Bonney will be honored with the second annual Massachusetts Biotechnology Council (MassBio) Innovative Leadership Award.
  Cubist Pharmaceuticals, Inc. March 15, 2010  
• Mipomersen Phase 3 study in HoFH patients featured in The Lancet  Genzyme and Isis Pharmaceuticals announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet.
  Isis Pharmaceuticals, Inc. March 15, 2010  
• Progenics announces fourth quarter and year-end 2009 financial results  Net loss for the fourth quarter was $0.6 million or $0.02, basic and diluted, per share, compared to $14.6 million or $0.48, basic and diluted, per share in the fourth quarter of 2008.
  Progenics Pharmaceuticals, Inc. March 15, 2010  

   (next 10 articles)